Literature DB >> 29079655

Reversible Transgene Expression Reduces Fratricide and Permits 4-1BB Costimulation of CAR T Cells Directed to T-cell Malignancies.

Maksim Mamonkin1,2, Malini Mukherjee3,4,5, Madhuwanti Srinivasan3, Sandhya Sharma3,6, Diogo Gomes-Silva3,7, Feiyan Mo3,6, Giedre Krenciute3,4, Jordan S Orange2,4,5,6, Malcolm K Brenner3,4,6.   

Abstract

T cells expressing second-generation chimeric antigen receptors (CARs) specific for CD5, a T-cell surface marker present on normal and malignant T cells, can selectively kill tumor cells. We aimed to improve this killing by substituting the CD28 costimulatory endodomain (28.z) with 4-1BB (BB.z), as 28.z CD5 CAR T cells rapidly differentiated into short-lived effector cells. In contrast, 4-1BB costimulation is known to promote development of the central memory subpopulation. Here, we found BB.z CD5 CAR T cells had impaired growth compared with 28.z CD5.CAR T cells, due to increased T-cell-T-cell fratricide. We demonstrate that TRAF signaling from the 4-1BB endodomain upregulated the intercellular adhesion molecule 1, which stabilized the fratricidal immunologic synapse between CD5 CAR T cells. As the surviving BB.z CD5 CAR T cells retained the desired central memory phenotype, we aimed to circumvent the 4-1BB-mediated toxicity using a regulated expression system that reversibly inhibits CAR expression. This system minimized CAR signaling and T-cell fratricide during in vitro expansion in the presence of a small-molecule inhibitor, and restored CAR expression and antitumor function of transduced T cells in vivo These studies reveal a mechanism by which 4-1BB costimulation impairs expansion of CD5 CAR T cells and offer a solution to mitigate this toxicity. Cancer Immunol Res; 6(1); 47-58. ©2017 AACR. ©2017 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29079655      PMCID: PMC5963729          DOI: 10.1158/2326-6066.CIR-17-0126

Source DB:  PubMed          Journal:  Cancer Immunol Res        ISSN: 2326-6066            Impact factor:   11.151


  48 in total

1.  AP2 adaptor complex-dependent internalization of CD5: differential regulation in T and B cells.

Authors:  Xianghuai Lu; Robert C Axtell; James F Collawn; Andrew Gibson; Louis B Justement; Chander Raman
Journal:  J Immunol       Date:  2002-06-01       Impact factor: 5.422

Review 2.  An enigmatic tail of CD28 signaling.

Authors:  Jonathan S Boomer; Jonathan M Green
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-06-09       Impact factor: 10.005

3.  ICAM-1-dependent homotypic aggregates regulate CD8 T cell effector function and differentiation during T cell activation.

Authors:  Nicholas A Zumwalde; Eisuke Domae; Matthew F Mescher; Yoji Shimizu
Journal:  J Immunol       Date:  2013-08-30       Impact factor: 5.422

4.  Lack of ICAM-1 on APCs during T cell priming leads to poor generation of central memory cells.

Authors:  Neetha Parameswaran; Radhakrishnan Suresh; Vineeta Bal; Satyajit Rath; Anna George
Journal:  J Immunol       Date:  2005-08-15       Impact factor: 5.422

Review 5.  Regulation of T-cell activation by the cytoskeleton.

Authors:  Daniel D Billadeau; Jeffrey C Nolz; Timothy S Gomez
Journal:  Nat Rev Immunol       Date:  2007-02       Impact factor: 53.106

6.  T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial.

Authors:  Daniel W Lee; James N Kochenderfer; Maryalice Stetler-Stevenson; Yongzhi K Cui; Cindy Delbrook; Steven A Feldman; Terry J Fry; Rimas Orentas; Marianna Sabatino; Nirali N Shah; Seth M Steinberg; Dave Stroncek; Nick Tschernia; Constance Yuan; Hua Zhang; Ling Zhang; Steven A Rosenberg; Alan S Wayne; Crystal L Mackall
Journal:  Lancet       Date:  2014-10-13       Impact factor: 79.321

7.  Chimeric antigen receptor T cells for sustained remissions in leukemia.

Authors:  Shannon L Maude; Noelle Frey; Pamela A Shaw; Richard Aplenc; David M Barrett; Nancy J Bunin; Anne Chew; Vanessa E Gonzalez; Zhaohui Zheng; Simon F Lacey; Yolanda D Mahnke; Jan J Melenhorst; Susan R Rheingold; Angela Shen; David T Teachey; Bruce L Levine; Carl H June; David L Porter; Stephan A Grupp
Journal:  N Engl J Med       Date:  2014-10-16       Impact factor: 91.245

8.  Human memory T cells express intercellular adhesion molecule-1 which can be increased by interleukin 2 and interferon-gamma.

Authors:  A M Buckle; N Hogg
Journal:  Eur J Immunol       Date:  1990-02       Impact factor: 5.532

9.  Protein kinase B controls transcriptional programs that direct cytotoxic T cell fate but is dispensable for T cell metabolism.

Authors:  Andrew N Macintyre; David Finlay; Gavin Preston; Linda V Sinclair; Caryll M Waugh; Peter Tamas; Carmen Feijoo; Klaus Okkenhaug; Doreen A Cantrell
Journal:  Immunity       Date:  2011-02-03       Impact factor: 31.745

10.  4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors.

Authors:  Adrienne H Long; Waleed M Haso; Jack F Shern; Kelsey M Wanhainen; Meera Murgai; Maria Ingaramo; Jillian P Smith; Alec J Walker; M Eric Kohler; Vikas R Venkateshwara; Rosandra N Kaplan; George H Patterson; Terry J Fry; Rimas J Orentas; Crystal L Mackall
Journal:  Nat Med       Date:  2015-05-04       Impact factor: 53.440

View more
  30 in total

Review 1.  Adoptive Cell Therapy for Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic Leukemia.

Authors:  Premal D Lulla; Maksim Mamonkin; Malcolm K Brenner
Journal:  Cancer J       Date:  2019 May/Jun       Impact factor: 3.360

Review 2.  [Combination of Oncolytic Virotherapy and CAR T/NK Cell Therapy for the Treatment of Cancer].

Authors:  G V Kochneva; G F Sivolobova; A V Tkacheva; A A Gorchakov; S V Kulemzin
Journal:  Mol Biol (Mosk)       Date:  2020 Jan-Feb

3.  CAR-T cell Therapy for Non-Hodgkin Lymphomas: A New Treatment Paradigm.

Authors:  LaQuisa Hill; Premal Lulla; Helen E Heslop
Journal:  Adv Cell Gene Ther       Date:  2019-03-28

Review 4.  The long road to the first FDA-approved gene therapy: chimeric antigen receptor T cells targeting CD19.

Authors:  Peter Braendstrup; Bruce L Levine; Marco Ruella
Journal:  Cytotherapy       Date:  2020-02-01       Impact factor: 5.414

Review 5.  Building a CAR Garage: Preparing for the Delivery of Commercial CAR T Cell Products at Memorial Sloan Kettering Cancer Center.

Authors:  Karlo Perica; Kevin J Curran; Renier J Brentjens; Sergio A Giralt
Journal:  Biol Blood Marrow Transplant       Date:  2018-03-01       Impact factor: 5.742

Review 6.  CAR T-cells for T-cell malignancies: challenges in distinguishing between therapeutic, normal, and neoplastic T-cells.

Authors:  Marion Alcantara; Melania Tesio; Carl H June; Roch Houot
Journal:  Leukemia       Date:  2018-10-12       Impact factor: 11.528

Review 7.  Signaling from T cell receptors (TCRs) and chimeric antigen receptors (CARs) on T cells.

Authors:  Ling Wu; Qianru Wei; Joanna Brzostek; Nicholas R J Gascoigne
Journal:  Cell Mol Immunol       Date:  2020-05-25       Impact factor: 11.530

Review 8.  CAR T cells for other pediatric non-B-cell hematologic malignancies.

Authors:  Adam J Lamble; Rebecca Gardner
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2020-12-04

Review 9.  State-of-Art of Cellular Therapy for Acute Leukemia.

Authors:  Jong-Bok Lee; Daniel Vasic; Hyeonjeong Kang; Karen Kai-Lin Fang; Li Zhang
Journal:  Int J Mol Sci       Date:  2021-04-27       Impact factor: 5.923

Review 10.  Riboswitches for Controlled Expression of Therapeutic Transgenes Delivered by Adeno-Associated Viral Vectors.

Authors:  Zachary J Tickner; Michael Farzan
Journal:  Pharmaceuticals (Basel)       Date:  2021-06-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.